Clinical Trial Update: HMPL-523 (Sovleplenib) in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia [Phase 2, Phase 3]

View source ↗

Summary

HMPL-523 (Sovleplenib) is being studied for warm autoimmune hemolytic anemia in Phase 2 and Phase 3, and the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Warm Autoimmune Hemolytic Anemia

Drugs mentioned

• Sovleplenib (HMPL-523)

Snippet

Sponsor: Hutchison Medipharma Limited | Conditions: Warm Antibody Autoimmune Hemolytic Anemia | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING